PubRank

Martin Sebastian

Author PubWeight™ 23.47‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012 4.44
2 A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 2012 1.83
3 Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008 1.74
4 Outcomes after percutaneous coronary intervention of ostial lesions in the era of drug-eluting stents. Catheter Cardiovasc Interv 2009 1.51
5 An evaluation of octogenarians undergoing percutaneous coronary intervention from the Melbourne Interventional Group registry. Catheter Cardiovasc Interv 2007 1.29
6 Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J Immunol 2008 1.08
7 Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer. Breast Cancer Res Treat 2010 1.05
8 The prognostic impact of blood group-related antigen Lewis Y and the ABH blood groups in resected non-small cell lung cancer. Tumour Biol 2008 1.00
9 Tissue microarrays are reliable tools for the clinicopathological characterization of lung cancer tissue. Anticancer Res 2009 0.96
10 Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2010 0.94
11 Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. Invest New Drugs 2014 0.92
12 A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer 2013 0.87
13 Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 2014 0.83
14 Are drug-eluting stents indicated in large coronary arteries? Insights from a multi-centre percutaneous coronary intervention registry. Int J Cardiol 2008 0.81
15 A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer. Lung Cancer 2013 0.80
16 Rates of stent thrombosis in bare-metal versus drug-eluting stents (from a large Australian multicenter registry). Am J Cardiol 2008 0.80
17 Renal impairment is an independent predictor of adverse events post coronary intervention in patients with and without drug-eluting stents. Cardiovasc Revasc Med 2008 0.80
18 TA-MUC1 epitope in non-small cell lung cancer. Lung Cancer 2008 0.80
19 Long-term predictors of mortality after percutaneous coronary intervention in the era of drug-eluting stents. Am J Cardiol 2011 0.77
20 Impact of periprocedural atrial fibrillation on short-term clinical outcomes following percutaneous coronary intervention. Am J Cardiol 2011 0.77
21 Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536. Oncol Res Treat 2017 0.75
22 Use of drug-eluting stents in Victorian public hospitals. Med J Aust 2006 0.75
23 Long-term Clinical Outcomes of Transient and Persistent No-Reflow Following Percutaneous Coronary Intervention (PCI): A Multi-Center Australian Registry. EuroIntervention 2017 0.75
24 Use of a portable device to record maximum inspiratory flow in relation to dyspnoea in patients with COPD. Respir Med 2010 0.75